In 2013, the US Preventive Services Task Force (USPSTF) recommended annual screening for lung cancer with low-dose computed tomography (LDCT) for adults aged 55 through 80 years who have a smoking history of at least 30 pack-years and currently smoke or have quit within the past 15 years (B recommendation).
1 These recommendations were largely based on the results of the National Lung Screening Trial (NLST).
2-4 Since then, new clinical guidelines have emerged for classifying and managing screening-detected pulmonary nodules,
5 and new evidence has emerged on the benefits and harms of LDCT screening.
6,7